Latest From Biogen Inc.
As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.
One Patient, Many Questions: Milasen ‘N of 1’ Trial Provides Early Template For Individualized Genomic Medicine
Rapid development of patient-customized oligonucleotide at Boston Children’s Hospital suggests promise and hazards of new drug development model.
Chinese regulatory agency working around the clock in preparation to release another official list of rare diseases, and a push to launch more innovative orphan drugs is underway. But this time pharma firms need to be more proactive, noted an NMPA official.
ALS advocates succeed in getting the FDA to soften its stance on use of randomized, placebo-controlled trials for drug development; final guidance also encourages patient-reported outcomes.
- Gene Therapy, Cell Therapy
- Drug Delivery
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Biogen Idec Inc.
- Biogen Inc.
- Idec Pharmaceutical Corp.
- North America
- Parent & Subsidiaries
- Biogen Inc.
- Senior Management
Michel Vounatsos, CEO
Jeffrey Capello, EVP, CFO
Alfred W Sandrock, Jr., MD, PhD, EVP, R&D & CMO
Daniel Karp, EVP, Corp. Dev.
Chirfi Guindo, EVP & Head, Global Mktg.
- Contact Info
Phone: (617) 679-2000
225 Binney St.
Cambridge, MA 02142
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.